Photo of Vanessa L. Merker,  PhD

Vanessa L. Merker, PhD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-6544


vmerker@mgh.harvard.edu

Photo of Vanessa L. Merker,  PhD

Massachusetts General Hospital
Phone: (617) 724-6544


vmerker@mgh.harvard.edu

Visualize Collaborations

Vanessa L. Merker, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Neurology, Harvard Medical School
  • Assistant Investigator, Neurology, Massachusetts General Hospital

HCC PROGRAM AFFILIATION

Research Abstract

I'm a health services researcher committed to improving healthcare for people with rare diseases by leveraging information collected directly from patients and their family members. My research focus is improving the accessibility, quality, and patient-centeredness of care for patients with the neurofibromatosis and schwannomatosis. To do this, I use qualitative and mixed methods research to understand patients healthcare needs and experiences; I develop and use patient reported outcome measures in clinical trials; and I engage patients as partners in the design and conduct of my research. I am highly experienced in neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis, and have broad interests across other rare, neurological and genetic conditions.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Da JLW, Merker VL, Jordan JT, Ly KI, Muzikansky A, Parsons M, Wolters PL, Xu L, Styren S, Brown MT, Plotkin SR. Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain. Contemp Clin Trials 2022; 121:106900. PubMed
  • Merker VL, Slobogean B, Jordan JT, Langmead S, Meterko M, Charns MP, Elwy AR, Blakeley JO, Plotkin SR. Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis. Am J Med Genet A 2022. PubMed
  • Merker VL, Knight P, Radtke HB, Yohay K, Ullrich NJ, Plotkin SR, Jordan JT. Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists. Orphanet J Rare Dis 2022; 17:44. PubMed
  • Wolters PL, Reda S, Martin S, Al Ghriwati N, Baker M, Berg D, Erickson G, Franklin B, Merker VL, Oberlander B, Reeve S, Rohl C, Rosser T, Toledo-Tamula MA, Vranceanu AM. Impact of the coronavirus pandemic on mental health and health care in adults with neurofibromatosis: Patient perspectives from an online survey. Am J Med Genet A 2022; 188:71-82. PubMed
  • Merker VL, Lessing AJ, Moss I, Hussey M, Oberlander B, Rose T, Thalheimer R, Wirtanen T, Wolters PL, Gross AM, Plotkin SR, . Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS. Neurology 2021. PubMed
  • Thalheimer R, Merker VL, Ly I, Champlain A, Sawaya J, Askenazi NL, Herr HP, Wei Da JL, Jordan JT, Muzikansky A, Pearce EM, Sakamoto FH, Blakeley J, Anderson RR, Plotkin SR, . [REiNS] Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials. Neurology 2021. PubMed
  • Wolters PL, Vranceanu AM, Thompson HL, Martin S, Merker VL, Baldwin A, Barnett C, Koetsier KS, Hingtgen CM, Funes CJ, Tonsgard JH, Schorry EK, Allen T, Smith T, Franklin B, Reeve S, . Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials. Neurology 2021; 97:S50-S63. PubMed
  • Radtke HB, Klein-Tasman BP, Merker VL, Knight P, Ullrich NJ, Jordan JT, Korf B, Plotkin SR. The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. Orphanet J Rare Dis 2021; 16:61. PubMed
  • Merker VL, Plotkin SR, Charns MP, Meterko M, Jordan JT, Elwy AR. Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis. Patient Educ Couns 2020. PubMed
  • Merker VL, Dai A, Radtke HB, Knight P, Jordan JT, Plotkin SR. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. BMC Health Serv Res 2018; 18:668. PubMed
  • Huang V, Bergner AL, Halpin C, Merker VL, Sheridan MR, Widemann BC, Blakeley JO, Plotkin SR. Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2. Otol. Neurotol. 2018; 39:632-638. PubMed
  • Vranceanu AM, Riklin E, Merker VL, Macklin EA, Park ER, Plotkin SR. Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT. Neurology 2016; 87:806-14. PubMed
  • Wolters PL, Martin S, Merker VL, Tonsgard JH, Solomon SE, Baldwin A, Bergner AL, Walsh K, Thompson HL, Gardner KL, Hingtgen CM, Schorry E, Dudley WN, Franklin B, . Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. Neurology 2016; 87:S4-S12. PubMed
  • Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. J Clin Oncol 2016. PubMed
  • Park ER, Smith KB, Merker VL, Muzikansky A, Vranceanu AM, Wang DL, Plotkin SR. Examining perceived cancer risk among patients with neurofibromatosis type 1. J. Neurooncol. 2015; 122:127-33. PubMed
  • Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol 2014. PubMed
  • Merker VL, Bredella MA, Cai W, Kassarjian A, Harris GJ, Muzikansky A, Nguyen R, Mautner VF, Plotkin SR. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A 2014. PubMed
Hide